Search
Descriptor English: Imipenem
Descriptor Spanish: Imipenem
Descriptor Portuguese: Imipenem
Descriptor French: Imipénem
Entry term(s): Anhydrous Imipenem
Anhydrous, Imipenem
Imipemide
Imipenem Anhydrous
Imipenem, Anhydrous
MK 0787
MK-0787
MK0787
N Formimidoylthienamycin
N-Formimidoylthienamycin
Tree number(s): D02.065.589.099.124.300.500
D03.633.100.300.124.300.500
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D015378
Scope note: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Anti-Bacterial Agents
Registry Number: 71OTZ9ZE0A
CAS Type 1 Name: 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R-(5alpha,6alpha(R*)))-
Previous Indexing: Antibiotics (1980-1982)
Thienamycins (1983-1988)
Public MeSH Note: 89
History Note: 89
DeCS ID: 28157
Unique ID: D015378
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1989/01/01
Date of Entry: 1988/06/03
Revision Date: 2016/05/31
Imipenem - Preferred
Concept UI M0023689
Scope note Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.
Preferred term Imipenem
Entry term(s) Imipemide
N Formimidoylthienamycin
N-Formimidoylthienamycin
Imipenem, Anhydrous - Narrower
Concept UI M0329530
Preferred term Imipenem, Anhydrous
Entry term(s) Anhydrous Imipenem
Anhydrous, Imipenem
Imipenem Anhydrous
MK-0787 - Narrower
Concept UI M0351093
Preferred term MK-0787
Entry term(s) MK 0787
MK0787



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.


Go to survey